Akari Therapeutics, Plc (NASDAQ:AKTX) was founded in 2004 and is headquartered in the United Kingdom with 17 full-time employees. It is a subsidiary of RPC Pharma Limited. It is a clinical-stage biopharmaceutical company focusing on a series of rare autoimmune and inflammatory diseases. Development and commercialization.
Akari Therapeutics, Plc (AKTX):
Akari focuses on the development of inhibitors of acute and chronic inflammation, especially the complement system and leukotriene system, for the treatment of rare diseases with unmet needs. The company believes that blocking the early mediators of inflammation will prevent the process that causes certain diseases from starting and expanding.
Coversin is a small recombinant protein (16,740 Da) that acts on the complement component-C5, prevents the release of C5a and the formation of C5b-9 (also called membrane attack complex, or MAC), and independently inhibits leukotriene B4 (LTB4) Active, the two elements work together as part of the immune/inflammatory response.
Coversin is currently undergoing clinical evaluation for four indications:
- Bullous pemphigoid (BP), a severe vesicular skin disease
- Atopic keratoconjunctivitis (AKC), an ocular surface that threatens vision
- Thrombotic microangiopathy (TMA) includes atypical hemolytic uremic syndrome (aHUS) and hematopoietic stem cell transplantation-related thrombotic microangiopathy (HSCT TMA)
- Paroxysmal nocturnal hemoglobinuria (PNH)
Akari believes that the dual effects of Coversin on C5 and LTB4 may be beneficial to AKC, BP and aHUS. Akari is also developing other tick-derived proteins, including longer-acting versions.
Coversin is a highly soluble and stable biomolecule that independently binds to C5 and LTB4. This novel dual combination makes it possible to target two different and independent disease categories based on their underlying etiology.